RT Journal Article
SR Electronic
T1 Efficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease A pragmatic multicenter, randomized, double-blind, placebo-controlled trial (CARR-COV-02)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.13.21255409
DO 10.1101/2021.04.13.21255409
A1 Juan M. Figueroa
A1 Mónica Lombardo
A1 Ariel Dogliotti
A1 Luis P. Flynn
A1 Robert P. Giugliano
A1 Guido Simonelli
A1 Ricardo Valentini
A1 Agñel Ramos
A1 Pablo Romano
A1 Marcelo Marcote
A1 Alicia Michelini
A1 Alejandro Salvado
A1 Emilio Sykora
A1 Cecilia Kniz
A1 Marcelo Kobelinsky
A1 David Salzberg
A1 Diana Jerusalinsky
A1 Osvaldo Uchitel
A1 CARR-COV2 Group Trial
YR 2021
UL http://medrxiv.org/content/early/2021/04/15/2021.04.13.21255409.abstract
AB Background Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as nasal spray in the treatment of common cold. In vitro, I-C inhibits SARS-CoV-2 infection in cell culture.Methods This is a pragmatic multicenter, randomized, double-blind, placebo-controlled trial assessing the use of a nasal spray containing I-C in the prophylaxis of COVID-19 in hospital personnel dedicated to care of COVID-19 patients.Clinically healthy physicians, nurses, kinesiologists and others medical providers were assigned in a 1:1 ratio to receive four daily doses of I-C spray or placebo for 21 days.The primary end point was clinical COVID-19, as confirmed by reverse-transcriptase–polymerase-chain-reaction testing, over a period of 21 days. The trial is registered at ClinicalTrials.gov (NCT04521322).Findings A total of 394 individuals were randomly assigned to receive I-C or placebo. Both treatment groups had similar baseline characteristics.The incidence of COVID19 was significantly lower in the I-C group compared to placebo (1·0% vs 5·0%) (Odds Ratio 0·19 (95% confidence interval 0·05 to 0·77; p= 0·03). Workday loss in placebo group compared to I-Cc were 1.6% days / person (95% ci, 1.0 to 2.2); p <0.0001There were no differences in the incidence of adverse events across the two groups (17·3% in the I-C group and 15·2% in the placebo group, p= 0·5).Interpretation I-C showed significant efficacy in preventing SARS-Cov-2 infection in hospital personnel dedicated to care patients with COVID-19 disease.Evidence before this study We searched PubMed for research articles published up to February 14, 2021, with no language restrictions, using the terms “SARS-CoV-2” or “COVID-19”, “prevention”, “clinical trial”, and “prophylaxis”. Except for studies on vaccines we only found three peer-reviewed publications available on the efficacy of Hydroxycholoquine to prevent COVID-19 disease in individuals at risk of exposure. Hydroxychloroquine did not prevent COVID-19 used as pre or postexposure prophylaxis. We also did not find results from clinical trials on the efficacy of carrageenan in the prevention or treatment of cOVID-19.Added value of this study We report the clinical efficacy of a nasal spray with Iota-Carrageenan for the prevention of COVID-19 disease in a randomised, double-blind, placebo-controlled, multicentre study in República Argentina, including 394 participants.Implications of all the available evidence A simple intervention such as the administration of a nasal spray with Iota-Carrageenan, in addition to hand hygiene, use of personal protective equipment and social distancing, could provide additional protection until vaccines can be administered to the majority of the population.Competing Interest StatementJMF and ML reports personal fees from Laboratorio Pablo Cassara, outside the submitted work.Clinical TrialNCT04521322Funding StatementThe study did not received support for hospitals, staff or patients involved. Publication and administrative costs were supported by: Programa de articulacion y fortalecimiento federal de las capacidades en ciencia y tecnologia COVID-19, Proyecto CABA 20. Ministerio de Ciencia, Tecnologia e Innovacion, Argentina. Laboratorio Pablo Cassara free provided the drug and placebo samples. Acknowledgements: We thank the participating hospitals, their staff and persons included in this study. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comite de Bioetica Hospital Interzonal General de Agudos Eva Peron de San Martin. General San Martin bioeticahospitalevaperon@hotmail.com Coordinador:Dr Jorge Manrique Comite de Etica Hospital Alta Complejidad El Cruce. Florencio Varela comitedeetica@hospitalelcruce.org Coordinador: Dra Soledad Giargei PintosAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the study findings are available within the paper.